## What is/are Propensity Adjusted Analysis?

Propensity Adjusted Analysis - A propensity-adjusted analysis was performed to assess POUR in neostigmine/glycopyrrolate versus sugammadex using inverse probability of treatment weighting (IPTW) to adjust for potential confounding.^{[1]}The risk of developing AKI was compared between these two combination therapies using propensity-adjusted analysis.

^{[2]}The authors aimed to compare MMA embolization versus conventional therapy for cSDHs using a propensity-adjusted analysis.

^{[3]}In propensity-adjusted analysis (n=528), children administered oral ondansetron were less likely to receive intravenous fluids at the index visit (adjusted odds ratio [aOR] 0.

^{[4]}Propensity-adjusted analysis revealed AVM resection without embolization was a risk factor for poor outcome (mRS score > 2; odds ratio, 4.

^{[5]}Conclusion At 2-year follow-up, propensity-adjusted analysis showed the thin strut (84–88um) Biomatrix Alpha CoCr-BP-BES was associated with improved clinical outcomes compared with the thicker strut (114–120um) Biomatrix Flex SS-BP-BES.

^{[6]}Univariate and multivariate analyses, including propensity adjusted analysis, were conducted introducing monotherapy type as an independent variable.

^{[7]}006) after propensity adjusted analysis.

^{[8]}In a planned sensitivity analysis, a propensity adjusted analysis for first-attempt success and a subgroup analysis of children < 2 years was also performed.

^{[9]}